75 Grey zone amyloid burden 24. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain : a journal of neurology. 2015;138(Pt 7):2020-33. 25. Landau SM, Horng A, Jagust WJ. Memory decline accompanies subthreshold amyloid accumulation. Neurology. 2018;90(17):e1452-e60. 26. Farrell ME, Chen X, Rundle MM, Chan MY, Wig GS, Park DC. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology. 2018;91(19):e1809-e21. 27. Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, et al. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res Ther. 2018;10(1):76. 28. van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer’s disease : JAD. 2018;62(3):1091-111. 29. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. Journal of Alzheimer’s disease : JAD. 2014;41(1):313-27. 30. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Threedimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Human brain mapping. 2003;19(4):224-47. 31. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligandreceptor binding in PET using a simplified reference region model. NeuroImage. 1997;6(4):279-87. 32. Highlights of prescribing information: Amyvid (florbetapir F18 injection): Food and Drug Administration; [Available from: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2012/202008s000lbl.pdf. 33. Verhage F, Van Der Werff JJ. [AN ANALYSIS OF VARIANCE BASED ON THE GRONINGER INTELLIGENCE TEST SCORES]. Nederlands tijdschrift voor de psychologie en haar grensgebieden. 1964;19:497-509. 34. Hassenstab J, Ruvolo D, Jasielec M, Xiong C, Grant E, Morris JC. Absence of practice effects in preclinical Alzheimer’s disease. Neuropsychology. 2015;29(6):940-8. 35. Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, et al. Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease. Biological psychiatry Cognitive neuroscience and neuroimaging. 2018;3(5):463-72. 36. Duff K, Foster NL, Hoffman JM. Practice effects and amyloid deposition: preliminary data on a method for enriching samples in clinical trials. Alzheimer disease and associated disorders. 2014;28(3):247-52. 37. Jutten RJ, Grandoit E, Foldi NS, Sikkes SAM, Jones RN, Choi SE, et al. Lower practice effects as a marker of cognitive performance and dementia risk: A literature review. Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring. 2020;12(1):e12055. 3
RkJQdWJsaXNoZXIy MjY0ODMw